GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PepGen Inc (NAS:PEPG) » Definitions » Financial Strength

PepGen (PepGen) Financial Strength : 7 (As of Mar. 2024)


View and export this data going back to 2022. Start your Free Trial

What is PepGen Financial Strength?

PepGen has the Financial Strength Rank of 7.

Good Sign:

PepGen Inc shows strong financial strength.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate PepGen's interest coverage with the available data. As of today, PepGen's Altman Z-Score is 0.00.


Competitive Comparison of PepGen's Financial Strength

For the Biotechnology subindustry, PepGen's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PepGen's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PepGen's Financial Strength distribution charts can be found below:

* The bar in red indicates where PepGen's Financial Strength falls into.



PepGen Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

PepGen's Interest Expense for the months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the months ended in Mar. 2024 was $-19.80 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $16.74 Mil.

PepGen's Interest Coverage for the quarter that ended in Mar. 2024 is

GuruFocus does not calculate PepGen's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. PepGen Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

PepGen's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.026 + 16.743) / 0
=N/A

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

PepGen has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PepGen  (NAS:PEPG) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

PepGen has the Financial Strength Rank of 7.


PepGen Financial Strength Related Terms

Thank you for viewing the detailed overview of PepGen's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


PepGen (PepGen) Business Description

Traded in Other Exchanges
N/A
Address
321 Harrison Avenue, 8th Floor, Boston, MA, USA, 02118
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.
Executives
James G Mcarthur director, officer: President and CEO NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Jaya Goyal officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Habib J Dable director C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
James E Flynn 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ra Capital Healthcare Fund Lp director, 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Laurie Keating director 300 THIRD STREET, CAMBRIDGE MA 02142
Christopher Ashton director PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Management Company, L.p. (series C) 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Michelle L Mellion officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Noel Donnelly officer: Chief Financial Officer PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Niels Svenstrup officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Sonia Bracegirdle officer: See Remarks PEPGEN INC., 245 MAIN ST., CAMBRIDGE MA 02142
Deerfield Mgmt V, L.p. 10 percent owner, other: *Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Private Design Fund V, L.p. 10 percent owner, other: *Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Oxford Science Enterprises Plc 10 percent owner 46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT